SIRT and Peri-immunotherapy : a New Concept

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · May 12, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment approach for patients with advanced liver cancer, specifically a type called hepatocellular carcinoma (HCC). The researchers want to see if combining selective internal radiation therapy (SIRT) with immunotherapy can be more effective than current treatments. SIRT is a procedure that uses radiation to target cancer cells in the liver, while immunotherapy helps the body’s immune system fight the cancer. Although early studies have shown promise, this trial aims to gather more information about how well this combination works and its long-term safety.

To be eligible for this trial, participants must be at least 18 years old and have a confirmed diagnosis of HCC with tumors larger than 6 cm. They should also have a specific score indicating their liver function (Child-Pugh score A to B7) and not be suitable for other curative treatments like surgery or transplants. The trial is not yet recruiting participants, but once it begins, those who qualify will receive the combination treatment of SIRT along with either atezolizumab or bevacizumab, both of which are types of immunotherapy. Participants will be closely monitored throughout the trial to assess the treatment’s effectiveness and any side effects.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years Diagnosis of hepatocellular carcinoma (HCC) confirmed by imaging or biopsy Tumor \> 6 cm Child-Pugh score A to B7 Not eligible for curative treatment (resection, ablation, transplant, TACE) Macrovascular invasion or AFP \> 100 ng/mL Treated with intra-arterial Yttrium-90 SIRT combined with atezolizumab ± bevacizumab
• Exclusion Criteria:
• • Age \< 18 Non-HCC diagnosis on imaging or pathology Child-Pugh \> B7 Prior immunotherapy or intra-arterial hepatic treatment Under legal guardianship or curatorship